SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksForterra Regulatory News (FORT)

Share Price Information for Forterra (FORT)

Share Price is delayed by 15 minutes
Get Live Data
130.20    2.40 (1.88%)
Bid:
130.00
Ask:
130.40
Spread: 0.40 (0.308%)
Market Cap: £268.15m
FORT Live PriceLast checked at - London Stock Exchange

Intraday Forterra Share Chart

2023 Trading Update

24 Jan 2024 07:00

RNS Number : 6815A
Forterra plc
24 January 2024
 

24 January 2024

FORTERRA PLC

 

2023 Trading Update

 

Adjusted EBITDA expected to be slightly ahead of the Board's previous expectations

 

Forterra plc (the 'Group'), a leading UK manufacturer of essential clay and concrete building products, provides its trading update for the year ended 31 December 2023.

 

Trading

 

· Full year revenue totalled c.£345m (2022: £455m), a year-on-year reduction of c.24%, with the impact of falling sales volumes partially offset by pricing benefits.

 

· Despite weak demand, pricing across our range of products remains resilient with modest 2024 price increases recently communicated.

 

· Figures published by the Department of Business and Trade highlight that UK brick despatches in the three-month period to November were 33% lower than the equivalent period in 2022, taking the cumulative YTD reduction to approximately 30%. As highlighted previously, our own despatches fell by a greater percentage driven by our exposure to volume housebuilding which suffered the greatest impact from rising interest rates.

 

· Despite continued challenging market conditions we expect to report full year adjusted EBITDA slightly ahead of the Board's expectations.

 

Management Actions

 

· Strong management actions during the year will deliver annualised fixed costs savings in excess of £20m with around £6m realised in 2023 with the balance in 2024. One-off cash restructuring costs are expected to total £9m of which £4m will be paid in 2024.

 

· Faced with increasing inventory levels, we made further reductions to production during the second half of 2023 which, assuming 2024 demand remains consistent with 2023, will ensure output is aligned with sales.

 

· Production has been reduced through the mothballing of factories, shift reductions and production breaks. In addition, we have delivered further savings through restructuring commercial and back-office functions.

 

· These temporary reductions will not impact our ability to respond quickly when our markets recover, with the new Desford brick factory also providing us with a significant capacity uplift.

 

Balance Sheet

 

· Reflecting our inventory build, capital expenditure and the management actions taken during 2023, year-end net debt before leases is expected to be c.£95m.

 

Outlook

 

· The outlook for our industry remains subject to considerable uncertainty and, with a general election expected in 2024, demand is anticipated to remain subdued in the near term.

 

· However, with the long term under supply of housing in the UK continuing to worsen, and UK brick despatches now running at levels last seen in 2009, the Board remains confident in the Group's ability to benefit as our key markets recover.

 

· Recent reductions in mortgage interest rates will improve the affordability of new homes, thus increasing demand for our products.

 

· The Group intends to announce its FY23 results on 26 March 2024.

 

 

ENQUIRIES

 

 

Forterra plc

+44 1604 707 600

Neil Ash, Chief Executive Officer

Ben Guyatt, Chief Financial Officer

FTI Consulting

+44 203 727 1340

Richard Mountain / Nick Hasell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOVWRSWUAUAR
Date   Source Headline
11th Jun 20262:52 pmRNSGrant under Long Term Incentive Plan
11th Jun 20267:00 amRNSDirectorate change
9th Jun 202611:53 amRNSHolding(s) in Company
9th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20269:45 amRNSTransaction in Own Shares
2nd Jun 202612:32 pmRNSEmployee Benefit Trust Share Purchase
2nd Jun 202612:30 pmRNSTotal Voting Rights and Capital
1st Jun 20267:00 amRNSAppointment of New Independent NED
27th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:03 pmRNSHolding(s) in Company
19th May 20264:41 pmRNSAnnual General Meeting 2026 Results
19th May 20267:01 amRNSTransaction in Own Shares
19th May 20267:00 amRNSAGM Trading Update
12th May 20261:32 pmRNSTransaction in Own Shares
12th May 20267:00 amRNSAGM RESOLUTION – APPROVAL OF REMUNERATION POLICY
7th May 20261:43 pmRNSHolding(s) in Company
6th May 202610:50 amRNSTransaction in Own Shares
6th May 20269:58 amRNSTotal Voting Rights and Capital
6th May 20269:55 amRNSEmployee Benefit Trust Share Purchase
28th Apr 202610:20 amRNSHolding(s) in Company
28th Apr 202610:18 amRNSTransaction in Own Shares
21st Apr 202611:31 amRNSTransaction in Own Shares
16th Apr 20267:00 amRNSEmployee Benefit Trust Share Purchase
15th Apr 20265:40 pmRNSNotice of Annual General Meeting 2026
14th Apr 202610:00 amRNSTransaction in Own Shares
14th Apr 20267:00 amRNSAppointment of new Independent NED
9th Apr 202610:15 amRNSHolding(s) in Company
9th Apr 20267:00 amRNSDirector Declaration
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20262:07 pmRNSTotal Voting Rights
7th Apr 202612:47 pmRNSEmployee Benefit Trust Share Purchase
31st Mar 20267:00 amRNSTransaction in Own Shares
30th Mar 20261:03 pmRNSDirector / PCA Shareholdings
25th Mar 202610:50 amRNSAnnual Report and Accounts 2025
24th Mar 202610:40 amRNSTransaction in Own Shares
24th Mar 20269:01 amRNSHolding(s) in Company
24th Mar 20267:00 amRNSReplacement:Grant under Deferred Annual Bonus Plan
20th Mar 20268:45 amRNSGrant under Deferred Annual Bonus Plan
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
17th Mar 20267:00 amRNSEmployee Benefit Trust Share Purchase
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
16th Mar 202610:32 amRNSLaunch of £20m Share Buyback Programme
11th Mar 20267:00 amRNSFull Year Results
3rd Mar 20263:27 pmRNSEmployee Benefit Trust Share Purchase
18th Feb 20262:27 pmRNSEmployee Benefit Trust Share Purchase
3rd Feb 202612:26 pmRNSEmployee Benefit Trust Share Purchase
29th Jan 20268:33 amRNSHolding(s) in Company
28th Jan 20269:21 amRNSHolding(s) in Company
26th Jan 20264:07 pmRNSHolding(s) in Company
22nd Jan 20267:00 amRNSFull Year 2025 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.